05-1-2019 Blog Posts

Largest Drug Makers Beat Profit Forecasts While Continuing To Price Gouge Patients Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday following earnings announcements from ten Big Pharma giants that showed they all surpassed profit forecasts for the first quarter of 2019. Drug maker GlaxoSmithKline (GSK) was the latest, announcing […]

Big Pharma Earnings Watch: Three More Pharma Giants Top Earnings Forecasts, Raise Outlooks

04-30-2019 Blog Posts

Three more earnings reports from drug makers show Big Pharma is doing just fine as rising prices continue to hammer American patients. Today, Big Pharma giants Eli Lilly, Merck and Pfizer released their quarterly profits.  All three companies beat earnings forecasts. Despite a drop in revenue, Eli Lilly still beat profit expectations. Merck earned $10.81 […]

Big Pharma Earnings Watch

04-27-2019 Blog Posts

Big Pharma Flying High: Sanofi & AstraZeneca Beat First Quarter Profit Forecasts, Continue Industry Trend  Another day, another pair of price-gouging Big Pharma companies announcing they had surpassed profit expectations for the first quarter of 2019. Drug makers AstraZeneca and Sanofi both announced this past Friday their earnings beat expectations for first quarter 2019.  The […]

Big Pharma Earnings Watch: Bristol-Myers Squibb

04-26-2019 Blog Posts

Trend Emerges: Bristol-Myers Squibb Joins Big Pharma Colleagues Beating First Quarter Profit Forecasts Another Big Pharma company announced higher than expected earnings – the latest in a growing trend indicating the industry continues to rake in profits, while facing greater scrutiny for rising prescription drug prices. Bristol-Myers Squibb reported better-than-expected earnings in the first quarter […]

Big Pharma Earnings Watch: AbbVie

04-26-2019 Blog Posts

AbbVie Beats Forecast But Dips In Revenue In Demonstration That Competition Lowers Prices AbbVie released its first quarter earnings and beat projections and raised its profit outlook.  CEO Richard Gonzalez said that the company was off to an “excellent start” for the year – the latest indication Big Pharma continues to thrive, while price-gouging American […]

Big Pharma Earnings Watch: Novartis

04-24-2019 Blog Posts

Novartis Beats Profit Forecasts After Jacking Up Prices On Dozens Of Drugs Big Pharma company Novartis announced higher than expected earnings today – beating forecasts and upping its projected profits for the year. How did the Swiss drug manufacturer make that happen?  By price-gouging American patients. Reports in December 2018 indicated Novartis planned to raise […]

Second Opinion: Boosted Ad Budgets Undercut Big Pharma’s R&D Rhetoric

04-17-2019 Blog Posts

New Report Finds Drug Makers Spent Whopping $6.46 Billion On Advertising In 2018 Big Pharma frequently claims high drug prices are necessary to fund research and development (R&D) for new cures.  A new report from Kantar Media underscores what we already know – that Big Pharma’s R&D excuse holds little water and that rising prices […]

“DOSE OF REALITY” | Calling Big Pharma’s Bluff On PBMs: Part V

04-9-2019 Blog Posts

Big Pharma has tried to evade culpability for the crisis of rising prescription drug prices by pointing a finger at pharmacy benefit managers (PBMs).  As the U.S. Senate Committee on Finance prepares to hear from the executives of five PBMs on April 9, it’s time to debunk Big Pharma’s bluffs.  PBMs serve an essential role […]

ICYMI: Lack Of Competition In Drug Market Drives Up Medicare & Medicaid Spending

03-18-2019 Blog Posts

In case you missed it, the Centers for Medicare and Medicaid Services (CMS) released new data last week which showed that prescription drugs with only one manufacturer are responsible for the biggest spending increases in both Medicare and Medicaid. According to the data, overall spending on prescription drugs under Medicare Part D increased at an […]

Good Medicine: Congress Should Pass Market-Based Solutions to Spur Prescription Drug Competition

03-13-2019 Blog Posts

The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act and the Fair Access for Safe and Timely (FAST) Generics Act are being discussed in a legislative hearing today before the U.S. House Energy & Commerce Subcommittee on Health.  The solutions contained in these market-based measures represent critical steps toward lowering prescription drug prices […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.